Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Inhibiting NLRC5 for hemolytic and inflammatory diseases

September 6, 2024 8:37 PM UTC

Inhibiting the cytosolic pathogen recognition receptor NLRC5 could help treat hemolytic and inflammatory diseases by preventing formation of the cell death PANoptosome complex in blood cells via interaction with NLRP12.

In bioinformatic analysis of public data sets, NLRC5 expression was higher in red blood cells from the blood and bone marrow of malaria patients than of individuals without malaria. In bioinformatic analysis of separate public data sets, NLRC5 expression was higher in blood monocytes and bone marrow hematopoietic stem cells from sickle cell disease patients than from individuals without sickle cell disease. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article